Drug Pipeline
PHASE2
● Phase II
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up
ClinicalTrials.gov
Published March 30, 2026
University of Colorado, Denver
NCT03617679 ↗
A phase II randomized controlled trial assessed rucaparib maintenance therapy versus placebo in 79 patients with metastatic or recurrent endometrial cancer who had received 1-2 prior lines of therapy. The primary outcome was progression-free survival (PFS), with follow-up reported at 55.8 months. The study sponsor was the University of Colorado, Denver.
No specific efficacy results for the primary PFS outcome are reported in the provided data. Effect size, absolute numbers, p-values, and direction of effect are all listed as not reported. Secondary outcomes were not specified in the input.
Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, are also not reported in the provided information. No specific study limitations were listed in the input.
As a completed phase II trial, this research represents an early-stage investigation. The absence of reported efficacy and safety outcomes prevents any assessment of rucaparib's potential benefit-risk profile in this setting. Clinicians should await peer-reviewed publication of the full trial results before considering any practice implications.
When endometrial cancer spreads or comes back after treatment, patients and doctors face a tough challenge: how to keep the cancer from advancing again. A recent clinical trial aimed to see if a drug called rucaparib, given as a maintenance therapy, could help women who had already tried one or two other treatments. The study involved 79 patients with metastatic or recurrent endometrial cancer. It was a phase II trial, which means it's an early step to see if the approach is worth pursuing in larger studies. The researchers were specifically looking at whether the drug could extend 'progression-free survival'—the time patients live without their cancer getting worse. The trial is now finished, but the key results on whether the drug actually delayed cancer progression, and any information on side effects or safety, haven't been reported yet. This means we simply don't know if the treatment helped or what its risks might be. The study was led by the University of Colorado, Denver. While the completion of the trial is a necessary step in research, it's important to wait for the actual data before drawing any conclusions about this potential treatment.
What this means for you: A trial for a maintenance drug in advanced endometrial cancer is done, but results aren't in yet.
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Metastatic Endometrial Cancer
Intervention(s): Rucaparib (DRUG), Placebo Oral Tablet (DRUG)
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
Detailed: This is a phase II clinical trial, that administers a maintenance treatment after first line chemotherapy is complete. It is designed to have a 1:1 randomization technique. Half the participants who enter the study will receive the active ingredient, Rucaparib, while the other half will receive a placebo. Treatment will be until progression with follow up until death.
Primary Outcome(s): Progression Free Survival (PFS)
Enrollment: 79 (ACTUAL)
Lead Sponsor: University of Colorado, Denver
Start: 2019-03-06 | Primary Completion: 2023-10-31
Results posted: 2024-07-01
